Potassium Carbonate Promoted C–N Coupling Reaction between Benzamides and Aryl Iodides
作者:Songlin Zhang、Fei Huang、San Wu、Weiye Hu
DOI:10.1055/s-0036-1591843
日期:2018.3
benzamides promoted by potassium carbonate in the presence of DMEDA was developed. The reaction was carried out without addition of any transition-metal catalyst to afford a variety of N-arylated products in moderate to good yields (up to 97%). A practical and efficient method for N-arylation of benzamides promoted by potassium carbonate in the presence of DMEDA was developed. The reaction was carried out
Efficient ligand-free copper-catalyzed N-arylation of amides with aryl halides in water
作者:Fui-Fong Yong、Yong-Chua Teo、Guan-Leong Chua、Gina Shiyun Lim、Yizhen Lin
DOI:10.1016/j.tetlet.2011.01.003
日期:2011.3
A convenient and efficient protocol has been developed for the cross-coupling of amides and aryl iodides using a ligand-freecopper(I) oxide catalyst in water. A variety of amide derivatives afforded the corresponding N-arylated products in moderate to good yields (up to 88%).
NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
申请人:Boléa Christelle
公开号:US20100137336A1
公开(公告)日:2010-06-03
The present invention relates to novel compounds of Formula (I), wherein X
1
, X
2
, X
3
, X
4
, A
m
and B
n
are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors.
The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
申请人:Bolea Christelle
公开号:US20110257182A1
公开(公告)日:2011-10-20
The present invention relates to novel compounds of Formula (I), wherein X
1
, X
2
, X
3
, X
4
, A
m
and B
n
are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors.
The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.